X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
male (3) 3
medicine, general & internal (3) 3
abridged index medicus (2) 2
aged (2) 2
angina (2) 2
cardiovascular diseases (2) 2
cardiovascular diseases - epidemiology (2) 2
cardiovascular diseases - mortality (2) 2
cerebral infarction (2) 2
dosage and administration (2) 2
double-blind method (2) 2
drug therapy (2) 2
female (2) 2
humans (2) 2
index medicus (2) 2
kaplan-meier estimate (2) 2
middle aged (2) 2
myocardial infarction (2) 2
myocardial-infarction (2) 2
11 medical and health sciences (1) 1
20s proteasome (1) 1
activation (1) 1
acute coronary syndrome (1) 1
acute coronary syndrome - drug therapy (1) 1
acute coronary syndrome; aged; anticholesteremic agents; azetidines; cardiovascular diseases; cholesterol, ldl; double-blind method; drug therapy, combination; ezetimibe; female; humans; hydroxymethylglutaryl-coa reductase inhibitors; kaplan-meier estimate; male; middle aged; simvastatin; triglycerides; medicine (all (1) 1
acute coronary syndromes (1) 1
adamantane (1) 1
adamantane - adverse effects (1) 1
adamantane - analogs & derivatives (1) 1
adamantane - therapeutic use (1) 1
aged, 80 and over (1) 1
all-cause (1) 1
analysis (1) 1
animals (1) 1
anticholesteremic agents (1) 1
anticholesteremic agents - adverse effects (1) 1
anticholesteremic agents - therapeutic use (1) 1
atorvastatin (1) 1
azetidines (1) 1
azetidines - adverse effects (1) 1
azetidines - therapeutic use (1) 1
behavioral disciplines and activities (1) 1
blotting, western (1) 1
cancer (1) 1
cardiac & cardiovascular systems (1) 1
cardiac death (1) 1
cardiac outcomes (1) 1
cardiology and cardiovascular system (1) 1
cardiovascular disease (1) 1
cardiovascular diseases - etiology (1) 1
cardiovascular diseases - prevention & control (1) 1
cardiovascular outcomes (1) 1
cholesterol (1) 1
cholesterol absorption (1) 1
cholesterol, ldl (1) 1
cholesterol, ldl - blood (1) 1
clinical-trials (1) 1
clinical-use (1) 1
complications and side effects (1) 1
cysteine endopeptidases - metabolism (1) 1
death (1) 1
defibrillators (1) 1
diabetes (1) 1
diabetes mellitus (1) 1
diabetes mellitus, type 2 (1) 1
diabetes mellitus, type 2 - complications (1) 1
diabetes mellitus, type 2 - drug therapy (1) 1
dipeptides (1) 1
dipeptides - adverse effects (1) 1
dipeptides - therapeutic use (1) 1
dipeptidyl-peptidase iv inhibitors (1) 1
dipeptidyl-peptidase iv inhibitors - adverse effects (1) 1
dipeptidyl-peptidase iv inhibitors - therapeutic use (1) 1
disease (1) 1
drug therapy, combination (1) 1
efficacy (1) 1
endotoxemia - metabolism (1) 1
endotoxemia - pathology (1) 1
escherichia coli (1) 1
events (1) 1
expression (1) 1
ezetimibe (1) 1
failure (1) 1
fluorescent antibody technique, indirect (1) 1
gallbladder (1) 1
general & internal medicine (1) 1
glucose control (1) 1
heart - drug effects (1) 1
heart attacks (1) 1
heart diseases (1) 1
heart failure (1) 1
heart failure - epidemiology (1) 1
heart rate (1) 1
hospitalization (1) 1
hospitalization - statistics & numerical data (1) 1
human health and pathology (1) 1
hydroxymethylglutaryl-coa reductase inhibitors (1) 1
hydroxymethylglutaryl-coa reductase inhibitors - adverse effects (1) 1
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (1) 1
hypoglycemia (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 06/2015, Volume 372, Issue 25, pp. 2387 - 2397
In this trial, patients with an acute coronary syndrome within the previous 10 days were randomly assigned to simvastatin plus either ezetimibe or placebo. At... 
CHOLESTEROL ABSORPTION | CARDIAC OUTCOMES | MEDICINE, GENERAL & INTERNAL | MYOCARDIAL-INFARCTION | EFFICACY | CARDIOVASCULAR OUTCOMES | CLINICAL-TRIALS | SIMVASTATIN | PRIMARY PREVENTION | IMPROVE-IT | ATORVASTATIN | Simvastatin - therapeutic use | Double-Blind Method | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Azetidines - adverse effects | Ezetimibe | Kaplan-Meier Estimate | Male | Anticholesteremic Agents - adverse effects | Acute Coronary Syndrome - drug therapy | Anticholesteremic Agents - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Azetidines - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Triglycerides - blood | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Cholesterol, LDL - blood | Female | Aged | Drug Therapy, Combination | Usage | Simvastatin | Analysis | Practice guidelines (Medicine) | Dosage and administration | Drug therapy, Combination | Acute coronary syndrome | Drug therapy | Myocardial infarction | Cerebral infarction | Lipoproteins (low density) | Stroke | Angina | Cholesterol | Intestine | Gallbladder | Acute coronary syndromes | Cardiovascular diseases | Statins | Pharmaceuticals | Cancer | Life Sciences | Human health and pathology | Cardiology and cardiovascular system
Journal Article
by Chatterjee, Neal A and Moorthy, M. Vinayaga and Pester, Julie and Schaecter, Andi and Panicker, Gopi K and Narula, Dhiraj and Lee, Daniel C and Goldberger, Jeffrey J and Kadish, Alan and Cook, Nancy R and Albert, Christine M and Elbert, Christine M and Mahal, Sharan and Sobolski, John and Danciu, Sorin and Dyke, Christopher and Phang, Robert and Wolinsky, David and Biederman, Robert and McLaurin, Brent and Trichon, Benjamin and Serfas, David and Aslam, Azhar and Bugni, William and Hany, Aziz and Jiang, Leng and Marais, Henri and Durr, Sam and Reinoehl, Joel and Graham, Susan and Sadler, Diego and Erenrich, Norman and Spencer, Robert and Griffin, John E.A and Geohas, Chris and Treasure, Charles B and Baki, Talal and Huneycutt, David and Saliba, Walid and Svinarich, J. Thomas and Whang, William and Jetty, Preetham and Shanes, Jeffrey and McGarvey, Joseph and Hankins, Shelley and White, Lindsey L and DeLurgio, David and Karunaratne, Harischandra and Flores, Enrique and Gillespie, Eve and McKenzie, John and Staniloae, Cezar and Altschuller, Alexander and Schuger, Claudio and Radin, Michael and Pohost, Gerald and Myers, Mark and Bunch, T. Jared and Wickemeyer, William and Mendelson, Robert and Berger, Ronald and Ross, Terence and Sumner, Andrew and Arcement, Lee and Malik, Bilal and Claxton, Ned and Rohr, Kathryn and Weiss, Robert and Garcia-Rinaldi, Raul and Kazmierski, John and Rosenbaum, David and Blonder, Ronald and Ramanathan, Kodangudi and O'Neill, Geariod and Cochran, Kevin and Kaufman, Elizabeth and Costantini, Otto and Hustead, Stephen and Sahul, Zakir and Bengston, James and Lader, Ellis and Nora, Matthew and Gornick, Charles and Adabag, Selcuk and Tishler, Steven and Klein, Steven and Lamas, Gervasio and Baig, Mirza and Ratliff, Michelle and Iwai, Sei and Johnson, Glover and Oliver, Thomas and Langer, Michael and Ahn, Joon and Silver, Kevin H and Mattson, Scott E and Schmidt, Jay and Ramanathan, P. Kasi and Heitner, John and Riba, Arthur and ... and PRE-DETERMINE Study Grp
JAMA Cardiology, ISSN 2380-6583, 07/2018, Volume 3, Issue 7, pp. 591 - 600
IMPORTANCE The majority of sudden and/or arrhythmic deaths (SAD) in patients with coronary heart disease occur in those without severe systolic dysfunction,... 
TRIAL | MORTALITY | POPULATION | DEFIBRILLATORS | CARDIAC & CARDIOVASCULAR SYSTEMS | MYOCARDIAL-INFARCTION | RISK-FACTOR | IMPLANTATION | CARDIAC DEATH | FAILURE | PREDICTION
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2013, Volume 369, Issue 14, pp. 1317 - 1326
Saxagliptin, a new oral antihyperglycemic drug in the DPP-4 inhibitor class, had no effect on the risk of cardiovascular events in patients with type 2... 
ALL-CAUSE | MEDICINE, GENERAL & INTERNAL | METAANALYSIS | EVENTS | GLUCOSE CONTROL | MICROALBUMINURIA | DISEASE | CLINICAL-USE | PREVENTION | RISK | DEATH | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Middle Aged | Hospitalization - statistics & numerical data | Male | Adamantane - therapeutic use | Aged, 80 and over | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Female | Hypoglycemia - chemically induced | Heart Failure - epidemiology | Diabetes Mellitus, Type 2 - complications | Adamantane - adverse effects | Adamantane - analogs & derivatives | Hypoglycemic Agents - therapeutic use | Cardiovascular Diseases - etiology | Dipeptides - therapeutic use | Double-Blind Method | Pancreatitis - epidemiology | Dipeptides - adverse effects | Kaplan-Meier Estimate | Pancreatitis - chemically induced | Aged | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Type 2 diabetes | Complications and side effects | Patient outcomes | Dosage and administration | Drug therapy | Heart diseases | Risk factors | Saxagliptin | Myocardial infarction | Cerebral infarction | Heart attacks | Peptidase | Diabetes mellitus | Pancreatitis | Cardiovascular disease | Angina | Patients | Heart rate | Ischemia | Diabetes | Cardiovascular diseases | Diabetes mellitus (non-insulin dependent)
Journal Article